There are two major ways in which cancer research and treatment have changed dramatically over the last 5 years [1] [2] [3] [4] [5] . The first is the progressive elucidation of the genetic basis of cancers, leading in turn to the definition of the molecular pathways that are hijacked in malignancy and to the identification and validation of new molecular targets for therapeutic intervention. The second is the development and implementation of a range of novel high-throughput technologies that are being used to accelerate the pace of gene discovery and the development of innovative therapies. These technologies include genomics, proteomics, high-throughput screening, combinatorial chemistry, structural biology and cassette dosing pharmacokinetics [3] [4] [5] . The present article will focus primarily on the impact of genomic and proteomic technologies on the development of new cancer drugs. Some background on genome sequencing will be provided and particular attention will be paid to the use of gene expression microarrays in cancer pharmacology and drug development.
Genome sequencing
The development of truly innovative molecular therapeutics relies on the discovery of new genes and biochemical pathways, from which pharmacologically tractable or 'druggable' targets can be identified [1] [2] [3] [4] [5] . The discovery of new genes is greatly enhanced by the high-throughput sequencing of the genomes of humans and other species. In February 2001, the working draft of the majority (93%) of the human genome sequence was published by the international public consortium and a rival private sector company [6, 7] . Although there has been debate about the scale of its immediate value, there can be little doubt that the availability of the genome sequence is revolutionising the way in which we approach biology and medicine [3, 4, [8] [9] [10] [11] [12] [13] . The scientific, political, ethical and commercial issues surrounding the Human Genome Project are described in Davies [14] , and Sulston and Ferry [15] .
The sequencing of the human genome is a quite outstanding technological achievement that has benefited greatly from developments in sequencing technology, based on the original dideoxy chain-termination method of Sanger [16] , but now incorporating fluorescent labelling, together with advances in automation and informatics [17] . It is extraordinary that the finished human sequence (with all gaps filled and errors corrected) will be available in 2003. This will be exactly 50 years after the publication, by Watson and Crick [18] , of the double helical structure of DNA that immediately provided an elegant physical explanation for the self-replication of the genome and for the mechanism of heredity [19] , as well as forming the basis of modern molecular biology and recombinant DNA technology (see also Watson [20] and Judson [21] ).
It is already clear that the 3 billion base pairs that make up the human sequence encode somewhere in the region of 26 000-40 000 genes. This is rather less than the 100 000 that was originally anticipated; as the popular press has taken up with curious relish, this is only double the gene count in the fruit fly Drosophila [22] . However, it is clear from the sequence that greater complexity is provided by the sophisticated assembly of protein domains in human genes [6, 7] , together with the large number of splice variants [23] . In addition, the extensive amount of human DNA (98% or more) that does not encode genes, contains the regulatory sequences that provide for the elaborate control of gene expression.
The advantages of genome-wide scale
One of the great benefits of the availability of the human genome sequence is the ability to study both normal biology and disease pathology on a genome-wide scale. Indeed this is a major defining characteristic of the postgenome era [8, 9] . It is now possible to 'collect' all the genes and to examine how their structure and expression changes in different situations; for example, under various perturbed conditions or in diseased versus healthy cells [9, 24] . In traditional biological and biomedical science the behaviour of only a single gene product, or of a small number of genes, would be monitored. It is now fairly straightforward to observe the expression of several thousand genes simultaneously and it will soon be possible to profile each and every gene in massively parallel fashion. The new genome-wide way of doing biomedical science has been criticised because it is not hypothesis-driven [15, 25] . This is the wrong way of viewing the genome-wide approach. The genome sequence should be considered as a fantastically powerful resource, and the ability to interrogate sequence and expression on a pan-genomic scale should be regarded as an unprecedented tool for hypothesis generation.
Some of the landmark publications in genome sequencing are listed in Table 1 and a selection of useful websites is given in Table 2 .
Cancer genomes
Cancer is clearly a genetic disease, in that it is caused by the mutation, amplification, deletion or abnormal expression of key genes that represent critical factors in the regulation of cell fate. Cancer-inducing genetic abnormalities may be inherited, or produced in somatic cells by carcinogenic insults. Cancer gene products are positioned at key regulatory nodes that control 'mission critical' biochemical signalling pathways [26] that in turn modulate the six hallmark traits of the cancer phenotype [27] . Cancer cells tend to:
1. Be self-sufficient in proliferative growth signalling, e.g. by activating the Ras pathway; 2. Develop insensitivity to growth inhibitory mechanisms, e.g. via loss of cell cycle controls; 3. Become resistant to apoptotic signals, e.g. by activation of the phosphoinositide 3′-kinase (PI3 kinase) pathway; 4. Acquire unlimited replicative potential, e.g. by activation of telomerase; 5. Induce a strong angiogenic response, e.g. in response to hypoxia via the HIF-1 pathway; and 6. Activate the processes of invasion and metastasis, e.g. through changes in matrix metalloproteases and adhesion molecules.
Our understanding of cancer genetics is now quite detailed, with around 100 dominant oncogenes (e.g. ras and myc) and 30 tumour suppressor genes (e.g. p53 and PTEN) already defined [28] . In addition to the dominant oncogenes ('accelerator' genes) and tumour suppressors ('gatekeeper' or 'brake' genes) there are also 'caretaker' cancer genes that are involved in regulating genome stability: loss of such genes, as for example in the case of the mismatch repair genes, can accelerate malignancy by increasing the rate of oncogenic mutations [28, 29] . Some general messages are emerging that are very important, both conceptually and also practically in terms of therapeutic exploitation. In particular, it is clear that several cancer genes normally act together in combination to drive the process of multistep malignant progression. It is likely that between four and seven critical genetic events are required for the development of common epithelial cancers [28] , as exemplified by the detailed elucidation of the genetics of colorectal cancer [29] . Individual oncogenes may dominate at certain stages in particular cancers and may thus be especially good therapeutic targets. This may well be the case for bcr-abl in early chronic myeloid leukaemia (CML) and for c-kit in gastrointestinal stromal tumours (GIST), thus explaining the effectiveness of imatinib in those cancers; another example may perhaps be erb2 in some breast tumours, leading to sensitivity to trastuzumab [1, 2] .
Genes involved in multistep oncogenesis can be defined by studies on clinical material [29] or by laboratory studies combining known oncogenes to define a minimal gene set affecting the mission critical pathways that lead particularly to deregulated cell proliferation and suppression of apoptosis [26] . In fact, cancer genes have been identified over the years by a variety of methods [30] . Many were found by dissecting chromosomal regions that are amplified (erbB2), translocated (bcr-abl) or deleted (p53, p16, PTEN). Genes such as ras that are activated by point mutation were discovered by transfection, while others, such as src were identified as the cellular homologues of transforming viral genes. The anti-apoptotic oncogene bcl2 was discovered in the nematode worm and studies in yeast and the fly have been vital to understanding the genetics of many critical oncogenic processes, including the Ras pathway and cell cycle control.
It is likely that there are a significant number of oncogenes still awaiting discovery, but it is difficult to know how many. The 'low hanging fruit', that is those genes characterised by major chromosomal abnormalities, have mostly been harvested already, although new oncogenes are still waiting to be found in some amplifications. The remaining cancer genes are likely to be more difficult to clone as they have no genomic flags with which to locate them, and low penetrance susceptibility genes are also hard to discover.
The availability of the draft human genome sequence has already proved invaluable in identifying cancer genes, examples being the breast cancer genes BRCA2 and the mismatch repair gene hMLH1 [31, 32] . However, although the speed of cancer gene discovery is enhanced by the human genome sequence, there are significant limitations. In a data mining exercise carried out with the working draft sequence, no new cancer genes could be identified by searching for paralogues of existing oncogenes and tumour suppressor genes [33] . This was probably not a surprise since cancer genes on the whole exhibit little sequence similarity with each other. It is also interesting that the same bioinformatic analysis was unable to identify known oncogenic fusion genes using public domain sequence from cancer cells and tissue, the main repository of which is the US National Cancer Institute's Cancer Genome Anatomy Project (CGAP; see www.ncbi.nlm. nih.gov.CGAP). In fact by whole genome standards the databases were found to contain relatively sparse cancer genome sequence, with much of the available sequence coming from untranslated rather than coding regions where oncogene mutations are usually located [33] .
Given the above limitations and to capitalise maximally on both the human genome sequence itself as well as the sequencing and bioinformatics capability established to complete the Human Genome Project, an initiative has been put in place to carry out whole genome sequencing of multiple representatives of the many different forms of human cancer [17, 34] . This UK-based Cancer Genome Project should help us to identify and catalogue all of the remaining cancer genes. Another limitation is that our knowledge of precisely how oncogenes combine in human malignancy remains limited. The sequencing of whole cancer genomes will help us to understand how groups of cancer-causing genes interact together to drive the malignant process. This should have major implications for cancer diagnosis and therapy [2] [3] [4] .
From cancer genomes to cancer therapeutics
The identification of the genes that are responsible for the development and progression of cancer, together with the elucidation of the biochemical functions of their cognate gene products and the cellular pathways that they operate within, Modified from Workman [3] . See also Clarke et al. [54] .
Human genome sequence http://www.ncbi.nlm.nih.gov/ http://genome.cse.ucsc.edu/ provides a rational and broad platform for mechanism-based therapeutic intervention. We are now beginning to test the hypothesis that by specifically modulating oncogenic targets and pathways it will be possible to develop innovative molecular therapeutics that are both more effective and have less severe side effects than the majority of current anticancers that are largely cytotoxic and antiproliferative in nature. Figure 1 illustrates schematically how the elucidation of the molecular biology, genomics and proteomics of cancer cells leads not only to the development of drugs acting on novel oncogenic targets, but also to the discovery of new molecular diagnostics, prognostics, pharmacodynamic endpoints and pharmacogenomic biomarkers. Also shown in Figure 1 is the importance of actively utilising these molecular biomarkers in the discovery, development and use of the new genome-based cancer drugs [1, 3, 4, 35, 36] . Combining cancer genomebased molecular biomarkers with cancer genome-based molecular therapeutics will allow us to test the vision of a personalised, combinatorial medical treatment for cancer that is targeted to the precise genomic and proteomic structure of the individual cancer patient and their malignancy. The beginnings of this can already be seen with the clinical activity and regulatory approval of imatinib [37] and trastuzumab [38] , both of which are licensed for use in genomically defined patient groups. It is difficult to predict exactly the extent to which the vision described above will be realised over the next 5-10 years. However, it is clear that we now have the molecular and genomic toolkit with which to carry out this grand clinical experiment.
The characteristics and potential advantages of postgenomic cancer drug development are summarised in Table 3 . This emphasises the way in which genomics and other new technologies are enhancing and accelerating the drug discovery process. In the past it has typically taken 10-15 years or more to progress from the identification of a drug target to the regulatory approval of a new drug [1] . The elucidation of the role of the bcr-abl translocation in CML began as early as 1960 but it has taken 40 years to develop a drug, imatinib, that blocks the molecular pathology of the disease. The ras oncogene was identified in 1982, but it is only recently that drugs that were designed to block the essential farnesylation and membrane localisation of the Ras protein have entered clinical trials [39] . In fact, there is considerable controversy about the precise molecular targets that are affected by protein farnesyl transferase inhibitors such as R115777 and SCH 66336. Acting downstream of Ras, drugs that inhibit Raf-1 (BAY-43-90060) and MEK (CI-1040) are also in clinical development [39] but only a considerable time after the pathway was Figure 1 . The application of genomics and proteomics in the development and use of novel cancer treatments. The molecular description and understanding of cancer is driving the discovery and development of a range of genome-based molecular therapeutics (see text). Already, in the cases of trastuzumab and imatinib, the selection of patients for therapy is based on the use of a molecular biomarker (e.g. ErbB2 and Bcr-Abl, respectively). A future scenario can be envisaged in which appropriate, personalised combinations of molecular therapeutics will be used (most likely alongside conventional therapies, at least for some time) according to the precise genomic and proteomic make-up of the individual patients and their malignancy. Modified from Workman and Kaye [1] .
worked out. As a final example of the time taken previously to translate cancer gene discovery into cancer drug development, the most commonly affected tumour suppressor in human cancer, p53, was discovered in 1977 and yet it is only in the last few years that small molecule drugs which might overcome or exploit defects in the p53 pathway have begun to appear to be technically feasible [40] . Gene therapy and virotherapy approaches based on p53 have entered clinical trials relatively recently [40] .
In a relatively short period of time we have moved far away from the position where new molecular targets for cancer therapy were few and far between, and where those that were known were certainly unprecedented in terms of clinical validity. There are now a large number of potential targets, some of which have been validated clinically, and important and difficult choices have to be made as to which to work on, not least because it can cost hundreds of millions of dollars to develop a drug all the way through to regulatory approval (allowing for attrition rates the figure is generally quoted as $500-800 million). Some of the criteria for the validation and selection of drug targets are summarised in Table 4 . It is important to appreciate that not all molecular targets that are attractive will prove pharmacologically tractable or 'druggable'. A protein-protein interaction may be too large to block with a small molecule and even some enzymes have active sites that are difficult to inhibit. In such cases it may be necessary to 'walk the pathway' in order to identify a more technically feasible drug target.
Another point to re-emphasise is the importance of having pharmacodynamic endpoint markers to facilitate the demonstration that the molecular target has been inhibited in preclinical models and in patients. Also, the potential for a molecular diagnostic/prognostic genomic markers to enable selection of patients most likely to benefit from the therapy is a major advantage.
Clearly, in selecting a potential target for a drug discovery programme, the frequency of genetic or epigenetic deregulation of the gene or pathway is an extremely important consideration, since this indicates the likelihood of causal involvement, as well as the number of patients that are likely to benefit. Molecular targets that are deregulated in relatively small numbers of patients may also be of great potential therapeutic importance in these particular patients, despite the fact that such targets are likely to be viewed as being of lower strategic and commercial value. This is an issue that will need Emphasis on new molecular targets that drive the molecular pathology and malignant progression of human cancers:
• provides an intellectual framework for discovering new drugs with improved efficacy and selectivity.
Application of modern technologies such as high-throughput screening, combinatorial chemistry, microarrays, structural biology and cassette dosing pharmacology:
• speeds up drug discovery and development.
Use of pharmacokinetic and pharmacodynamic endpoints:
• enhances the rationality and hypothesis-testing power of clinical trials, provides the basis for early stop/go decisions and reduces the risk at late-stage failure.
Utilisation of diagnostic, prognostic and pharmacogenomic molecular biomarkers:
• facilitates the targeting of individualised treatments to patients most likely to benefit. Table 4 . Criteria for validation and selection of new drug targets a a Note that not all criteria need to be met to embark on a drug discovery programme. However, if several of these criteria are met, it provides increasing confidence and reduces risk for the project. Modified from Workman and Kaye [2] .
• Frequency of genetic or epigenetic deregulation of the target or pathway in human cancer.
• Demonstration in a model system that the target contributes to the malignant phenotype.
• Evidence of the reversal of the malignant phenotype; for example, by gene knockout, dominant negative, antisense, RNAi, antibodies, peptides or drug leads.
• Practical feasibility, tractability or 'druggability' of the target; for example, enzymes are commonly more tractable than are most protein-protein interactions.
• Availability of a robust, efficient and informative biological test cascade to support the drug discovery programme.
• Ability to build and run a cost-effective high-throughput screen.
• Availability of a structure-based drug design approach.
• Potential for the use of molecular diagnostic/prognostic markers and pharmacodynamic endpoints.
to be addressed as the genomic stratification of cancers gains momentum.
Examples of new molecular therapeutics
Some examples of newly emerging targets and molecular therapeutics are summarised below, with comments on aspects of current interest. New technologies and cancer genomics have contributed in a major way to the discovery and development of these agents. For more details see, for example, Workman and Kaye [1] . In some cases the targets and agents involved are such that activity would be expected in particular, genomically-defined subsets of patients. Other examples include agents that inhibit targets for which therapeutic effects will be applicable across a broader range of patients.
Imatinib
Already mentioned above, imatinib (Glivec) has shown striking early activity in CML and GIST. Working via the inhibition of the kinase activity of Bcr-Abl and c-Kit, respectively, imatinib can be seen as a paradigm of postgenomic mechanism-based drug discovery [37] . Current issues include the development of resistance arising via mutation or amplification of bcr-abl, the optimal way to use the drug in combination, and the potential for activity in other tumour types.
Drugs acting on the ErbB family
The humanised monoclonal antibody trastuzumab (Herceptin) set the original precedent for genome-based cancer drugs, receiving approval for the treatment of ErbB2-positve breast cancers [38] . A genome-based assay is therefore required for patient selection. Significant side-effects are however seen when trastuzumab is used in combination with cytotoxic drugs. Other monoclonal antibodies, notably cetuximab (IMS-C225) which targets the epidermal growth factor (EGF) receptor, are also under development. Small molecule inhibitors of various members of the ErbB family of receptor tyrosine kinases are now emerging [38] . The most advanced is gefitinib (Iressa), which inhibits the EGF receptor kinase and shows activity in non-small-cell lung, head and neck, and hormone-resistant prostate cancer. The optimal use of gefitinib in drug combinations remains to be defined and the role of potential prognostic makers needs to be explored.
Inhibitors of the Ras/Raf/MAP kinase cascade
Drugs that inhibit the farnesylation of Ras proteins (e.g. R115777 and SCH66336) or the downstream kinases Raf-1 (BAY-43-9006) and MEK (CI-10-40) have already been referred to and are showing promise in preclinical and early clinical development [39] . It is extremely difficult to select the most appropriate locus for pharmacological intervention in a given pathway, not least because of signalling redundancy and crosstalk. For a discussion of this issue see Workman and
Kaye [2] and Herrara and Sebolt-Leopold [39] . The development of computer algorithms to predict optimal intervention sites in silico is a likely future development.
PI3 kinase inhibitors
Often depicted as operating downstream of Ras or in parallel with the Raf-1 to MAP kinase pathway, signalling through PI3 kinase is another mission critical pathway in cancer. It is clearly important for a range of oncogenic characteristics, including proliferation, inhibition of apoptosis and angiogenesis. Cancers frequently activate the PI3 kinase pathway by loss of the phosphatase tumour suppressor gene PTEN or alternatively via amplification or increased expression of the PI3 kinase p110α or the downstream kinase Akt/PKB. Thus PI3 kinase inhibitors could provide considerable therapeutic benefit [2] .
Therapies based on p53
Various approaches based on the p53 pathway are now being evaluated preclinically and clinically [40] . As mentioned previously, gene replacement therapy for tumours with mutant p53 is already undergoing clinical evaluation. The Onyx O-15 virus selectively replicates in and kills tumour cells lacking p53 function and is now undergoing clinical trials. Small molecule compounds have been discovered that stabilise the wild-type conformation and function of mutant p53. Inhibitors of the binding between p53 and Hdm2 have been described; these could be useful in malignancies where wild-type p53 is disabled by this interaction. A small molecule, pithithrin α, has been reported to inhibit p53-dependent gene transcription and apoptosis and this has the potential to be used to protect normal tissues from cytotoxic and radiation therapy. The agent leptomycin B has been shown to block nuclear export of p53. The appropriate choice of p53-based therapeutic would be dependent on the precise molecular status of the p53 pathway in a given cancer.
Cyclin-dependent kinase-inhibitors
Deregulation of the cell cycle is very common, if not universal, in cancer. Evidence suggests that inhibitors of cyclindependent kinases (CDKs) could restore cell cycle control or induce apoptosis in tumour cells with deregulated E2F. A number of inhibitors, e.g. of CDKs 1, 2 and 4, are now in preclinical and clinical development, including flavopiridol and the R-enantiomer of roscovitine (CYC202) [41] . Current issues include the optimal selectivity of inhibitors across the family of CDKs and the emerging non-cell cycle roles for various CDKs in normal tissues [42] .
Modulators of epigenetic control and chromatin-based regulation of gene expression
Epigenetic silencing of a number of genes, such as p14ARF, p16/INK4a and b, BRCA1 and MLH1, by methylation of cytosine residues is very important in malignancy [42] . The inhibitor of DNA methyltransferase, decitabine, can reverse epigenetic silencing and is now undergoing clinical trials. Gene expression is also controlled by the acetylation of lysine residues on the tails of histones in chromatin [43, 44] . Histone deacetylases (HDACs) and histone acetyl transferases (HATs) are deregulated in cancers, supporting their potential as drug targets [43] . A number of HDAC inhibitors are now in preclinical and clinical development and HAT inhibitors are also being sought. Recent discoveries show that histone tails are modified not only by acetylation but also by other covalent 'marks', such as methylation, phosphorylation, ADP ribosylation and ubiquitination, in a fashion that constitutes a histone code [44] . Deregulation of this code is likely to be important in cancer and in other diseases. Identification of the genes involved in adding and subtracting the various histone marks will provide a range of potential new targets for therapeutic intervention [3] . Treatment could be based on a diagnostic platform that exploits epigenomics and 'histonomics' [2, 42] .
Proteasome inhibitors
A number of important oncogenic and regulatory proteins are degraded by the ubiquitin proteasome pathway. Proteasome inhibitors therefore show promise as potential cancer drugs and one of these, PS-341, has shown evidence of clinical activity in cancer [45] .
Hsp90 molecular chaperone inhibitors
This is yet another example, to add to several above, where the proximal therapeutic target of the drug is not a cancer gene product per se, but rather a regulatory molecule that controls the fate of oncogenic factors. The hsp90 gene family is responsible for the correct folding, conformation and function of various oncogenic 'client protein' molecules such as ErbB2, AKT/PKB, Raf-1, CDK4, mutant p53 and sex hormone receptors. Inhibition of Hsp90 targets these molecules for proteasomal degradation. Hsp90 inhibitors therefore cause simultaneous blockade of a number of oncogenic pathways, which is a major potential attraction [46, 47] . The first-in-class Hsp90 inhibitor 17AAG is now in clinical trial. Inhibition of the target has been shown by demonstrating depletion of client proteins and elevation of the biomarker Hsp70, and some evidence of clinical disease stabilisation has been reported.
Drugs acting on HIF-1 signalling for angiogenesis
The transcription factor HIF-1 is a major player in the angiogenic switch that is triggered in response to the development of tumour hypoxia [48] . HIF-1α function is also regulated by PI3 kinase, Akt/PKB and FRAP/mTOR (mammalian target of rapamycin). Inhibitors of HIF-1 signalling are actively sought. Rapamycin-based inhibitors of FRAP/mTOR are already undergoing clinical trial.
Suicide gene therapy and virotherapy
The present review has focused heavily on small molecule approaches to cancer therapy. These can have a pharmacokinetic advantage. Macromolecular strategies are also important, but are currently limited by the availability of effective vectors for systemic delivery. Two of the most promising approaches include suicide gene therapy and virotherapy, the latter being exemplified by the Onyx O-15 virus. Both have the important property of so-called 'bystander' killing [49] .
Gene expression microarrays and proteomics in cancer pharmacology
One of the major objectives of the Human Genome Project is to understand and predict all biological behaviour in terms of gene structure and expression. It seems obvious that cell function, for both the normal and the diseased states, will be best understood by determining the expression patterns of all of the genes in the genome, rather than just a few. Preferably this would be done at the level of both messenger RNA (the transcriptome) and also functional protein (the proteome).
With the presently available technology, the transcriptome is more readily accessible than the proteome. Various methods have been developed for measuring global messenger RNA expression (including serial analysis of gene expression or SAGE [50] ) and of these the gene expression microarray method has rapidly developed into an important laboratory tool [51] [52] [53] [54] . Gene expression microarray analysis is a major practical benefit of genome sequencing. Any sequence, from a previously known or newly identified gene through to an expressed sequence tag (EST) corresponding to an as yet unknown gene, can be spotted or constructed on the array. DNA microarrays are based on the fundamental property of nucleic acid hybridisation and are essentially a massively parallel version of northern and Southern blotting. There are two principle technologies: (i) the Affimetrix gene chip which employs prefabricated chips where oligonucleotides are synthesised on the array in situ by photolithography or other methods; and (ii) custom made spotted arrays in which cDNA, oligonucleotides or polymerase chain reaction (PCR) products are deposited robotically on glass slides or nylon membranes.
In addition to being used for probing gene expression profiles at the mRNA level, DNA microarrays can be used for other purposes; for example, the detection of amplifications, deletions or mutations. In the last couple of years, there has been an explosion of papers describing the use of microarrays, both cDNA-based and oligonucleotide-based, to interrogate the transcriptomes of cancer cells and tissues [51] [52] [53] [54] . The majority of studies have focused on cataloguing the gene expression signatures of various cancers, and on looking for patterns that predict subclasses with clinical significance. Early studies in breast cancer [55] and lymphoma [56] illustrated the power of microarrays when used in this way.
It is now becoming clear that gene expression microarrays have a major role to play in all stages of modern drug development from target discovery and validation all the way through to clinical evaluation and even potentially in routine drug usage [52] [53] [54] . For example, they can be utilised to figure out relationships between basal gene expression patterns and the sensitivity of cancer cells to drugs [57] . Because the transcriptome is very dynamic and responsive to changing circumstances, it is a very sensitive indicator of how the cell is responding ('measuring the delta'). A major interest of my own laboratory is in understanding how the transcriptome changes in response to drug treatment and to determine whether alterations in gene expression patterns can be predictive of sensitivity or resistance to novel or established agents, as well as to discover molecular pharmacodynamic markers of drug selectivity and resistance [54] . This approach is exemplified by our work with the Hsp90 molecular chaperone inhibitor 17AAG [58] . Determination of gene expression changes that represent 'on-target' effects (i.e. those that are direct consequences of pharmacological modulation of the molecular target) as distinct from 'off-target' effects (which may relate more to the chemical backbone of that drug) can provide extremely useful information. Defining a molecular signature of gene expression that is characteristic of the inhibition of a particular molecular target, as we have done with Hsp90 inhibitors such as 17AAG [54, 58] , provides a powerful means to track mechanisms of sensitivity and resistance and to identify valuable biomarkers of response.
The type of information obtained, can be used both in terms of comparing gene expression patterns in different cell types and also with respect to profiling the pharmacological effects of actual or potential drugs. Changes in gene expression observed using microarrays require confirmation by alternative technologies, such as northern and western blotting, RNAse protection assays, ELISA or real-time PCR.
Microarray technology has quickly become much more user-friendly and affordable. In our hands the results obtained are very reproducible although care has to be taken to determine the variation of gene expression patterns with drug concentration, time of exposure and the nature of the cell or tissue under study. With improvements in the methodology and hardware, it is clear from our experience that the rate-limiting step is now the bioinformatic analysis-interpreting the complex patterns that are observed and figuring out their significance. Data mining methods such as hierarchical clustering and multiple dimensional scaling, available in the public domain or commercially, are extremely useful [54, 59] . It has become clear that a major challenge lies in following up new and unexpected areas of biology that are highlighted by array analysis. In many cases the changes in gene expression could not be predicted ahead of time and of course the identification of the unexpected is a major strength of gene expression microarray analysis. Linkage of array databases to functional databases and literature mining tools is therefore very valuable.
The field of proteomics has also shown considerable advances over the last few years. The goal here is to be able to monitor the expression patterns, peptide sequence and posttranslational modifications (e.g. phosphorylation, acetylation, etc.) of all proteins that are expressed in the cell and then to determine the complex interactions between the proteins and, of course, understand the biological significance of the results obtained. For more detailed information on proteomics the reader is referred to Blackstock and Mann [60] . In our own experience (in collaboration with Prof. Mike Waterfield's laboratory) proteomic analysis has proved highly complementary to gene expression microarray analysis in determining the detailed response of cancer cells to drugs. For example, we have found that some genes are modulated by a drug at either the mRNA level or at the protein level but not necessarily both. In the case of Hsp90 inhibitors, client proteins, such as Raf-1, are depleted at the protein level but the mRNA levels are unaffected [58] . On the other hand, in the case of the Hsp70 family, inhibition of Hsp90 leads to an up-regulation of gene expression at both the mRNA and the protein level [58] . If interpreted carefully, such data can be extremely informative, rather than confusing.
Concluding remarks
Genome-based technologies are having a profound effect on all stages of the development of new anticancer drugs. Of particular note has been the rise of gene expression microarray technology which is being used in a number of ways: for basic biology; target identification and validation; compound and drug profiling; discovery of genes that predict response or resistance and detection of pharmacodynamic endpoints [54] . It is now readily feasible to monitor changes in thousands of genes within samples taken from patients treated with a conventional or investigational cancer drug. Proteomic technology is not yet so user-friendly but when carried out in expert laboratories, analysis of the proteome is extremely powerful.
One of the key issues is now data handling [59] . Improved, user-friendly databases are needed to help extract all the important information from the mass of data that can be collected. Databases that allow comparisons to be made across a broad range of investigations in different laboratories and fields are urgently needed.
The technology is now available to profile the genomes of individual patients and their cancers and then to base medical decision-making on the genomic readout. With the completion of the Human Genome Project, we will soon be able to monitor the expression of all human genes in any given setting. While it is clear that genomic and proteomic technologies are having an enormous impact on basic and preclinical experimentation, and also now on investigational clinical research, it is less obvious when and how chip technology will impact on routine treatment. This will be dependent on userfriendliness and costs. Although access and use is increasing, the availability of DNA microarrays and proteomics is still restricted to a relatively small proportion of the potential community. The actual conduct of the process of DNA microarray and proteomic analysis is carried out in a very much smaller number of laboratories. Access and use will be improved when each technology moves on to become a single, ready to use piece of bench-top equipment. Technical developments in miniaturisation, microfluidics, label-free detection and analysis software will be especially important [60] . Use of chips to analyse the entire transcriptome or proteome in a routine pathology laboratory, or even at the point of care, would be an extraordinary step forward.
Although it has been argued that it may take significant time for genome sequencing to impact directly on routine cancer therapy [35] , the remarkable pace of technological achievement is likely to continue to surprise us. Who will pay for such sophisticated technology is likely to be a more difficult problem to solve. There is no doubt, however, that genomics is already having a profound effect on drug discovery and development. The combination of selective cancer-genome based therapeutics used alongside genome-derived molecular biomarkers has the potential to usher in a new era of personalised cancer therapy.
